Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis

Author:Tuan Vu  Stojan Peric  Pushpa Narayanaswami  Marek Smilowski  Agnieszka Slowik  Sankalp Gokhale  Caitlin Briggs  Uzma Siddiqui  Simrat Randhawa  Matt Truman  Luke Hickey  Shahar Shelly  John Vissing  

Topic:Autoimmune Neurology  

Program Number:C5.002  P2.015  

Author Institution:University of South Florida, Tampa, FL  University of Belgrade, Belgrade, Serbia  Beth Israel Deaconess Medical Center, Boston, MA  Neurologia Slaska Centrum Medyczne, Katowice, Poland  University Hospital, 31-007 Krakow, Poland  Dianthus Therapeutics, Cincinnati, OH  Dianthus Therapeutics, Raleigh, NC  Dianthus Therapeutics, Amherst, NY  Dianthus Therapeutics, New York, NY  Truman Statistical Services, Dee Why, Australia  Dianthus Therapeutics, King Of Prussia, PA  Rambam Medical Center, Haifa, Israel  University of Copenhagen, Copenhagen, Denmark  

Impact of Time Since Diagnosis on Inebilizumab Efficacy: Post-hoc Phase 3 MINT Trial Data Analysis

Author:Ali Habib  James Howard  Michael Benatar  Emma Ciafaloni  M. Isabel Leite  Kimiaki Utsugisawa  John Vissing  Sarah Bray  Michaela Schlader-Ratzinger  Catherine Najem  Blanca Canales  Sue Cheng  Richard Nowak  

Topic:Autoimmune Neurology  

Program Number:P1.053  

Author Institution:University of California, Irvine, Irvine, CA, USA, Orange, CA  University of North Carolina, Chapel Hill, NC, USA, Chapel Hill, NC  University of Miami Miller School of Medicine, Miami, FL, USA, Miami, FL  University of Rochester, Rochester, NY, USA, Rochester, NYHanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  Amgen Ltd., Cambridge, United Kingdom  Amgen Inc., Thousand Oaks, CA, USA, Vienna, Austria  Amgen Inc., Thousand Oaks, CA, USA, Horsham, PA  Amgen Inc., Thousand Oaks, CA, USA, Humble, TXYale University School of Medicine, New Haven, CT, USA, New Haven, CT  

Phase 3 Myasthenia Gravis Inebilizumab Trial (MINT): Minimal Symptom Expression Achievement with Inebilizumab

Author:Richard Nowak  Michael Benatar  Emma Ciafaloni  M. Isabel Leite  Kimiaki Utsugisawa  John Vissing  Sarah Bray  Blanca Canales  Kristina Patterson  Catherine Najem  Sue Cheng  James Howard  

Topic:Autoimmune Neurology  

Program Number:P1.055  

Author Institution:Yale University, New Haven, CT, USA, New Haven, CT  University of Miami Miller School of Medicine, Miami, FL, USA, Miami, FL  University of Rochester, Rochester, NY, USA, Rochester, NYHanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  Amgen Ltd., Cambridge, United Kingdom  Amgen Inc., Thousand Oaks, CA, USA, Humble, TXAmgen Inc., Thousand Oaks, CA, USA, Horsham, PAUniversity of North Carolina, Chapel Hill, NC, USA, Chapel Hill, NC